Neuroblastoma mRNAs Predict Outcome in Children With Stage 4 Neuroblastoma: A European HR-NBL1/SIOPEN Study

Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children's Oncology Group

(2013) G. A. Yanik et al.   JOURNAL OF NUCLEAR MEDICINE

The prognostic value of fast molecular response of marrow disease in patients aged over 1year with stage 4 neuroblastoma

(2011) J. Stutterheim et al.   EUROPEAN JOURNAL OF CANCER

Multiple target molecular monitoring of bone marrow and peripheral blood samples from patients with localized neuroblastoma and healthy donors

(2011) Maria Valeria Corrias et al.   PEDIATRIC BLOOD & CANCER

Prognostic Impact of Gene Expression–Based Classification for Neuroblastoma

(2010) André Oberthuer et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study

(2010) Ruth Ladenstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Recent Advances in Neuroblastoma

(2010) John M. Maris   NEW ENGLAND JOURNAL OF MEDICINE

International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee

(2009) P F Ambros et al.   BRITISH JOURNAL OF CANCER

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force

(2009) K Beiske et al.   BRITISH JOURNAL OF CANCER

Detecting Minimal Residual Disease in Neuroblastoma: Still a Ways to Go

(2009) B. Kagedal   CLINICAL CHEMISTRY

Detecting Minimal Residual Disease in Neuroblastoma: The Superiority of a Panel of Real-Time Quantitative PCR Markers

(2009) J. Stutterheim et al.   CLINICAL CHEMISTRY

Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study

(2009) Joëlle Vermeulen et al.   LANCET ONCOLOGY

Exploiting Gene Expression Profiling to Identify Novel Minimal Residual Disease Markers of Neuroblastoma

(2008) I. Y. Cheung et al.   CLINICAL CANCER RESEARCH

mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis

(2008) Catarina Träger et al.   INTERNATIONAL JOURNAL OF CANCER

PHOX2BIs a Novel and Specific Marker for Minimal Residual Disease Testing in Neuroblastoma

(2008) Janine Stutterheim et al.   JOURNAL OF CLINICAL ONCOLOGY

The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report

(2008) Tom Monclair et al.   JOURNAL OF CLINICAL ONCOLOGY

The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

(2008) Susan L. Cohn et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal disease monitoring by QRT-PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials

(2008) VF Viprey et al.   JOURNAL OF PATHOLOGY

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial

(2008) Andrew DJ Pearson et al.   LANCET ONCOLOGY